PolyVascular
Tim Moran is a prominent entrepreneur and executive with extensive experience in pediatric medical device development. As Founder and CEO of PediaStent since 2012, Tim is leading the development of CardiaZn, a pioneering bioresorbable metallic stent for treating congenital heart defects in neonates, recognized by the FDA as a Break Through Technology in 2023. Additionally, Tim founded PediaVascular in 2010, which has successfully treated over 80,000 infants in 25 countries with innovative angiography devices. With leadership roles at PediaWorks, the Midwest Pediatric Device Consortium, and PolyVascular, Tim has made significant contributions to the pediatric healthcare sector. Tim’s previous experience includes founding CSF Therapeutics and serving as Entrepreneur in Residence at Cleveland Clinic. Tim holds an MBA from Northwestern University's Kellogg School of Management and a BS in Finance from Miami University.
This person is not in any teams
PolyVascular
Children born with congenital heart defects may require frequent surgeries that prevent them from living their lives to the fullest. PolyVascular provides the only non-surgical pulmonary valve and delivery system suitable for children as young as 2 years old. Our minimally invasive valve reduces the need for open heart surgery and enables kids to enjoy a healthy, normal lifestyle. Current animal tissue valves often cause endocarditis, while human tissue grafts may sensitize the child's immune system. We address these limitations with our biocompatible, durable, polymer-based valve. Our valve, provided with an-easy-to-use delivery system for clinicians, is easy to manufacture at any size.